Patents by Inventor Sergio Abrignani

Sergio Abrignani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hepatitis C virus E2 binding protein
    Patent number: 7320875
    Abstract: HCV assays are described. The assays utilize a 24 kd protein capable of binding the E2 envelope protein of hepatitis C virus (HCV), or functionally equivalent variants or fragments of the 24 kd protein.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: January 22, 2008
    Assignee: Chiron S.r.l.
    Inventor: Sergio Abrignani
  • Assay to detect HCV receptor binding
    Publication number: 20070298410
    Abstract: Identification of HCV receptor target cells using HCV receptor-binding ligands and cell separation by flow cytofluorimetry is described. HCV receptor target cells are employed to conduct assays for HCV receptor-binding ligands in order to identify potential HCV vaccine candidates. HCV receptor target cells are used to measure antibody neutralisation to monitor vaccine development, as a diagnostic of HCV infection and to develop neutralising antibodies for passive immunisation.
    Type: Application
    Filed: April 6, 2007
    Publication date: December 27, 2007
    Inventor: Sergio Abrignani
  • Method for the preparation of purified HCV RNA by exosome separation
    Publication number: 20070254351
    Abstract: The invention relates to a method for isolation of hepatitis C virus. The method comprises the separation of particles termed exosomes from the blood plasma of an individual infected with hepatitis C virus (HCV) and the extraction or RNA from these exosome particles.
    Type: Application
    Filed: January 30, 2007
    Publication date: November 1, 2007
    Inventors: Sergio Abrignani, Piero Pileri
  • Hepatitis C receptor protein CD81
    Publication number: 20070087407
    Abstract: The present invention relates to the use of CD81 protein and polynucleic acid in the therapy and diagnosis of hepatitis C and pharmaceutical compositions, animal models and diagnostic kits for such purposes.
    Type: Application
    Filed: July 28, 2006
    Publication date: April 19, 2007
    Inventors: Sergio Abrignani, Guido Grandi
  • Method for the preparation of purified HCV RNA by exosome separation
    Patent number: 7198923
    Abstract: The invention relates to a method for the isolation of hepatitis C virus. The method comprises the separation of particles termed exosomes from the blood plasma of an individual infected with hepatitis C virus (HCV) and the extraction or RNA from these exosome particles.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: April 3, 2007
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Sergio Abrignani, Piero Pileri
  • Hepatitis C receptor protein CD81
    Patent number: 7097987
    Abstract: The present invention relates to the use of CD81 protein and polynucleic acid in the therapy and diagnosis of hepatitis C and pharmaceutical compositions, animal models and diagnostic kits for such purposes.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: August 29, 2006
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Sergio Abrignani, Guido Grandi
  • Binding protein
    Publication number: 20060166193
    Abstract: HCV assays are described. The assays utilize a 24kd protein capable of binding the E2 envelope protein of hepatitis C virus (HCV), or functionally equivalent variants or fragments of the 24kd protein.
    Type: Application
    Filed: March 9, 2006
    Publication date: July 27, 2006
    Inventor: Sergio Abrignani
  • Binding protein
    Patent number: 7026130
    Abstract: A 24kd protein capable of binding the E2 envelope protein of hepatitis C virus (HCV), and functionally equivalent variants or fragments of the 24kd protein, are disclosed. Processes for production and purification of the 24kd protein, and functionally equivalent variants or fragments thereof, are also disclosed, as are methods for using the protein to screen for chemical compounds that bind HCV.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: April 11, 2006
    Assignee: Chiron Corporation
    Inventor: Sergio Abrignani
  • T cell activation
    Publication number: 20050281793
    Abstract: A method for antigen independent activation of T cells comprising contacting T cells with a combination of cytokines such as two or more of interleukin-2, interleukin-6 and tumor necrosis factor ?.
    Type: Application
    Filed: July 19, 2005
    Publication date: December 22, 2005
    Applicant: Chiron S.p.A.
    Inventor: Sergio Abrignani
  • Hepatitis C receptor protein CD81
    Publication number: 20040258694
    Abstract: The present invention relates to the use of CD81 protein and polynucleic acid in the therapy and diagnosis of hepatitis C and pharmaceutical compositions, animal models and diagnostic kits for such purposes.
    Type: Application
    Filed: June 3, 2004
    Publication date: December 23, 2004
    Applicant: Chiron SPA
    Inventors: Sergio Abrignani, Guido Grandi
  • Binding protein
    Publication number: 20040180053
    Abstract: A functionally unglycosylated transmembrane protein having a molecular weight of about 24 kd which is ubiquitous in human cells and exhibits the same species specificity as hepatitis C virus. The protein is capable of binding to HCV surface proteins and is a putative HCV cellular receptor. As such it has many applications in the fields of diagnosis and treatment of HCV infection and in the design of HCV therapeutics.
    Type: Application
    Filed: March 18, 2004
    Publication date: September 16, 2004
    Applicant: Chiron S.p.A.
    Inventor: Sergio Abrignani
  • Binding protein
    Patent number: 6777538
    Abstract: A 24 kd protein capable of binding the E2 envelope protein of hepatitis C virus (HCV), and functionally equivalent variants or fragments of the 24 kd protein, are disclosed. Processes for production and purification of the 24 kd protein, and functionally equivalent variants or fragments thereof, are also disclosed.
    Type: Grant
    Filed: January 5, 2001
    Date of Patent: August 17, 2004
    Assignee: Chiron S.r.l.
    Inventor: Sergio Abrignani
  • Method for preparing HCV E2 binding protein
    Patent number: 6737233
    Abstract: A 24 kd percent capable of binding the E2 envelope protein of hepatitis C virus (HCV), and functionally equivalent variants or fragments of the 24 kd protein, are disclosed. Processes for production and purication of the 24 kd protein, and functionally equivalent variants or fragments thereof, are also disclosed.
    Type: Grant
    Filed: February 17, 1998
    Date of Patent: May 18, 2004
    Assignee: Chiron S.r.l.
    Inventor: Sergio Abrignani
  • Intracellular production of hepatitis C E1 and E2 truncated polypeptides
    Publication number: 20040001854
    Abstract: Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.
    Type: Application
    Filed: February 18, 2003
    Publication date: January 1, 2004
    Inventors: Michael Houghton, Qui-Lim Choo, Sergio Abrignani, David Chien, Mark Selby, Edward Glazer
  • Intracellular production of Hepatitis C E2 polypeptides
    Patent number: 6521423
    Abstract: Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: February 18, 2003
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, Sergio Abrignani, David Chien, Mark Selby, Edward Glazer
  • Eliciting HCV-specific antibodies
    Publication number: 20020002272
    Abstract: Described herein is a method of eliciting antibodies and neutralizing of binding antibodies against a hepatitis C virus (HCV) E1E2 or E2 antigen using HCV E2 or HCV E1E2 polypeptides and/or HCV E2 or E1E2 polynucleotides. Elicitation of anti-E2 antibodies and anti-E2 NOB antibodies can be used, inter alia, to provide model systems to optimize anti-E2 antibody responses and/or anti-E2 NOB antibody responses to HCV and to provide prophylactic or therapeutic treatment against HCV infection.
    Type: Application
    Filed: December 1, 2000
    Publication date: January 3, 2002
    Inventors: Michael Houghton, Mark Selby, Sergio Abrignani, Jens Martin Heile, Derek O'Hagan
  • Binding protein
    Publication number: 20010027565
    Abstract: A 24 kd protein capable of binding the E2 envelope protein of hepatitis C virus (HCV), and functionally equivalent variants or fragments of the 24 kd protein, are disclosed. Processes for production and purification of the 24 kd protein, and functionally equivalent variants or fragments thereof, are also disclosed.
    Type: Application
    Filed: January 5, 2001
    Publication date: October 4, 2001
    Applicant: Chiron S.p.A.
    Inventor: Sergio Abrignani
  • T cell activation
    Patent number: 6074635
    Abstract: Methods for activating T cells in the absence of antigen, and compositions for effecting the same, are described.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: June 13, 2000
    Assignee: Chiron Corporation
    Inventor: Sergio Abrignani